Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioharvest Sciences (BHST) Common Equity (2023 - 2025)

Bioharvest Sciences has reported Common Equity over the past 3 years, most recently at $25.4 million for Q4 2025.

  • For Q4 2025, Common Equity rose 1813.38% year-over-year to $25.4 million; the TTM value through Dec 2025 reached $25.4 million, up 1813.38%, while the annual FY2025 figure was $25.4 million, 1813.38% up from the prior year.
  • Common Equity was $25.4 million for Q4 2025 at Bioharvest Sciences, up from $7.7 million in the prior quarter.
  • Across five years, Common Equity topped out at $25.4 million in Q4 2025 and bottomed at -$83.5 million in Q4 2023.
  • The 3-year median for Common Equity is $4.1 million (2024), against an average of -$6.1 million.
  • The widest YoY moves for Common Equity: up 1813.38% in 2025, down 163.01% in 2025.
  • Over 3 years, Common Equity stood at -$83.5 million in 2023, then soared by 101.59% to $1.3 million in 2024, then skyrocketed by 1813.38% to $25.4 million in 2025.
  • The last three reported values for Common Equity were $25.4 million (Q4 2025), $7.7 million (Q3 2025), and -$4.2 million (Q2 2025) per Business Quant data.